Literature DB >> 34956445

Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma.

Balaji Ramachandran1, Thangarajan Rajkumar1, Gopal Gopisetty1.   

Abstract

EWS-FLI1 is a master regulator of Ewing sarcoma (ES) oncogenesis. Although EWS-FLI1 represents a clear therapeutic target, targeted therapeutic inhibitors are lacking. Scientific literature has indicated accumulating information pertaining to EWS-FLI1 translocation, pathogenesis, function, oncogenic partnerships, and potential clinical relevance. However, attempts to develop EWS-FLI1-driven human-like ES mouse models or in vivo systems ended up with limited success. Establishing such models as preclinical screening tools may accelerate the development of EWS-FLI1 targeted therapeutic inhibitors. This review summarizes the current scenario, which focuses on the limitations, challenges, and possible reasons for past failures in model development and also plausible interim alternatives. AJTR
Copyright © 2021.

Entities:  

Keywords:  EWS-FLI1; Ewing sarcoma; fusion protein; mouse models; progenitor cells; tumor cell of origin

Year:  2021        PMID: 34956445      PMCID: PMC8661172     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  109 in total

1.  Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study.

Authors:  Gregory T Armstrong; Toana Kawashima; Wendy Leisenring; Kayla Stratton; Marilyn Stovall; Melissa M Hudson; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

2.  Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II.

Authors:  E O Burgert; M E Nesbit; L A Garnsey; E A Gehan; J Herrmann; T J Vietti; A Cangir; M Tefft; R Evans; P Thomas
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

3.  Antisense oligonucleotide nanocapsules efficiently inhibit EWS-Fli1 expression in a Ewing's sarcoma model.

Authors:  Nedjma Toub; Jean-Rémi Bertrand; Claude Malvy; Elias Fattal; Patrick Couvreur
Journal:  Oligonucleotides       Date:  2006

4.  Health status of the oldest adult survivors of cancer during childhood.

Authors:  Lisa B Kenney; Cheryl Medeiros Nancarrow; Julie Najita; Lynda M Vrooman; Monica Rothwell; Christopher Recklitis; Frederick P Li; Lisa Diller
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

5.  The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts.

Authors:  Stephen L Lessnick; Caroline S Dacwag; Todd R Golub
Journal:  Cancer Cell       Date:  2002-05       Impact factor: 31.743

Review 6.  Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.

Authors:  Aykut Uren; Jeffrey A Toretsky
Journal:  Future Oncol       Date:  2005-08       Impact factor: 3.404

7.  A conditional mouse model of synovial sarcoma: insights into a myogenic origin.

Authors:  Malay Haldar; Jeffrey D Hancock; Cheryl M Coffin; Stephen L Lessnick; Mario R Capecchi
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

8.  EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis in vivo.

Authors:  Eun Jung Sohn; Hongjie Li; Karen Reidy; Lisa F Beers; Barbara L Christensen; Sean Bong Lee
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

9.  EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.

Authors:  Rikuka Shimizu; Miwa Tanaka; Shuichi Tsutsumi; Hiroyuki Aburatani; Yukari Yamazaki; Mizuki Homme; Yoshimasa Kitagawa; Takuro Nakamura
Journal:  Cancer Sci       Date:  2018-07-18       Impact factor: 6.716

10.  An EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of Impaired Osteogenic Differentiation on Osteosarcoma Development.

Authors:  Shingo Komura; Katsunori Semi; Fumiaki Itakura; Hirofumi Shibata; Takatoshi Ohno; Akitsu Hotta; Knut Woltjen; Takuya Yamamoto; Haruhiko Akiyama; Yasuhiro Yamada
Journal:  Stem Cell Reports       Date:  2016-03-17       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.